

Cara Therapeutics, Inc.
Form 3
January 30, 2014

FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0104
Expires: January 31, 2015
Estimated average burden hours per response... 0.5

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section
30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *	2. Date of Event Requiring Statement	3. Issuer Name and Ticker or Trading Symbol
Â Menzaghi Frederique Ph.D.	(Month/Day/Year)	Cara Therapeutics, Inc. [CARA]
(Last) (First) (Middle)	01/30/2014	
	4. Relationship of Reporting Person(s) to Issuer	5. If Amendment, Date Original Filed(Month/Day/Year)
C/O CARA THERAPEUTICS, INC.,Â 1 PARROTT DRIVE	(Check all applicable)	
(Street)	____ Director ____ 10% Owner	6. Individual or Joint/Group Filing(Check Applicable Line)
	<input checked="" type="checkbox"/> Officer ____ Other	<input checked="" type="checkbox"/> Form filed by One Reporting Person
SHELTON,Â CTÂ 06484	(give title below) (specify below)	____ Form filed by More than One Reporting Person
(City) (State) (Zip)	VP-Research & Development	

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	160,000	D	Â

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)	3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
		Title			

Edgar Filing: Cara Therapeutics, Inc. - Form 3

	Date Exercisable	Expiration Date		Amount or Number of Shares		or Indirect (I) (Instr. 5)	
Employee Stock Option (Right to Buy)	Â (1)	07/11/2015	Common Stock	20,000	\$ 0.25	D	Â
Employee Stock Option (Right to Buy)	Â (1)	11/07/2017	Common Stock	20,000	\$ 2.48	D	Â
Employee Stock Option (Right to Buy)	Â (1)	08/14/2018	Common Stock	10,000	\$ 2.25	D	Â
Employee Stock Option (Right to Buy)	Â (2)	10/15/2020	Common Stock	40,000	\$ 2.05	D	Â

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Menzaghi Frederique Ph.D. C/O CARA THERAPEUTICS, INC. 1 PARROTT DRIVE SHELTON, CT 06484	Â	Â	Â VP-Research & Development	Â

Signatures

/s/Darren DeStefano,
Attorney-in-Fact

01/30/2014

Signature of Reporting Person

Date

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 5(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) Immediately exercisable.

(2) This option vests and becomes exercisable over a four-year period as follows: 25% of the shares underlying the option vested on October 15, 2011 with the remainder vesting in equal monthly installments over the following 36 months.

Â

Remarks:

Exhibit List - Exhibit 24 - Power of Attorney

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.